HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Hyperfibrinogenolysis in disseminated adenocarcinoma.

AbstractWe present the case of a 42-year-old woman with a recently acquired bleeding tendency. Coagulation studies and response to antifibrinolytic therapy suggested primary hyperfibrinogenolysis: markedly low levels of fibrinogen and alpha2-antiplasmin, normal levels of antithrombin III, protein C and protein S combined with an only borderline low number of platelets without evidence of microangiopathic haemolytic anaemia. A suspected causative adenocarcinoma of the lung was demonstrated. She was treated successfully with tranexamic acid and cryoprecipitate, until the tumor progressed and hyperfibrinogenolysis progressed to diffuse intravascular coagulation. Differential diagnosis of these coagulation disorders, with similar etiology, clinical and laboratory findings is reviewed. Therapeutic implications are discussed.
AuthorsK Meijer, W M Smid, S Geerards, J van der Meer (Affiliation: Division of Thrombosis, Haemostasis and Rheology, University Hospital Groningen, The Netherlands. k.meijer at int.azg.nl)
JournalBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 9 Issue 3 Pg. 279-83 (Apr 1998) ISSN: 0957-5235 [Print] ENGLAND
PMID9663712 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antifibrinolytic Agents
  • Fibrin Fibrinogen Degradation Products
  • alpha-2-Antiplasmin
  • fibrin fragment D
  • Tranexamic Acid
  • Fibrinogen
Topics
  • Adenocarcinoma (complications, diagnosis)
  • Adult
  • Afibrinogenemia (diagnosis, etiology)
  • Antifibrinolytic Agents (therapeutic use)
  • Brain Ischemia (etiology)
  • Diagnosis, Differential
  • Disease Progression
  • Disseminated Intravascular Coagulation (diagnosis, etiology)
  • Fatal Outcome
  • Female
  • Fibrin Fibrinogen Degradation Products (analysis)
  • Fibrinogen (metabolism)
  • Hemorrhagic Disorders (blood, etiology)
  • Humans
  • Lung Neoplasms (blood, complications, diagnosis)
  • Paraneoplastic Syndromes (blood, diagnosis, etiology)
  • Tranexamic Acid (therapeutic use)
  • alpha-2-Antiplasmin (deficiency)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD